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Development of cytokine resistance is an important
feature of melanoma cells during tumor progression.
To study the mechanisms of interleukin-6 resistance,
we examined an interleukin-6 sensitive (WM35) and
an interleukin-6 unresponsive cell line (WM9).
Interleukin-6 treatment resulted in rapid inhibition
of cyclin-dependent kinase 2/cyclin E activity and
accumulation of the hypophosphorylated retinoblas-
toma protein in WM35 but not in WM9 cells. In
contrast to previous reports, no differences in the
expression of the cyclin-dependent kinase 2 inhibitor
p21Cip1/WAF1 upon interleukin-6 treatment were
found in both cell lines. Interleukin-6-induced inhib-
ition of cyclin-dependent kinase 2 was also not due
to changes in protein expression of cyclin-dependent
kinase 2, cyclin E, p27Kip1 and cdc25A, a phosphatase
positively regulating cyclin-dependent kinase 2 activ-
ity. As it is established that interleukin-6 resistance of
WM9 cells is not caused by differential interleukin-6
receptor expression, we studied whether this is due
to defective interleukin-6 signaling in which acti-
vation of signal transducer and activator of transcrip-
tion 3 is a critical step. WM9 cells showed reduced
tyrosine phosphorylation, DNA binding, and delayed
nuclear translocation of signal transducer and activa-
tor of transcription 3 as compared with WM35 cells.
The kinase upstream of signal transducer and activa-
tor of transcription 3, Janus kinase 1, was constitu-
tively tyrosine-phosphorylated in WM9 cells and did
not respond to interleukin-6 with increased phos-
phorylation. As compared with WM35 cells, interleu-
kin-6 treatment of WM9 cells was not paralleled by
reduced activity of the mitogen-activated protein
kinase kinase-1, which suppresses activation of signal
transducer and activator of transcription 3. Our data
suggest that resistance of advanced melanoma cells
to interleukin-6 is associated with reduced inhibition
of cyclin-dependent kinase 2, which appears to be a
consequence of a complex alteration in interleukin-6
signal transduction. Key words: cell cycle/interleukin-6/
melanoma/signal transduction/signal transducer and activa-
tor of transcription 3. J Invest Dermatol 117:132±140, 2001
T
ransformation of normal melanocytes to aggressive
metastatic melanoma cells is a multistep process
de®ned by distinct stages in situ and in vitro.
According to the tumor model proposed by Clark
(1991a) and Elder et al (1993), melanomas develop
from precursor lesions, i.e., benign nevi (congenital or common
acquired), or from normal melanocytes to become so-called
dysplastic lesions that are capable of malignant transformation.
These premalignant lesions can progress into in situ melanomas with
melanocytic cells strictly con®ned to the epidermis, and subse-
quently to radial growth phase (RGP) melanomas, which have the
same features as in situ melanomas except that individual tumor cells
have invaded the dermis. Surgical excision of RGP melanomas is
mostly curative (Clark, 1991b), indicating a reduced metastatic
potential of the in®ltrating cells. If left untreated, RGP melanomas
become invasive by undergoing a vertical growth phase in which
the tumor cells acquire the capability to metastasize.
In the last years distinct biologic features have also been
elaborated in vitro between normal human melanocytes and
melanoma cell lines derived from different stages of disease
progression. Whereas normal human melanocytes in vitro strin-
gently require the synergistic action of distinct growth factors such
as basic ®broblast growth factor (bFGF), mast cell growth factor,
hepatocyte growth factor, and endothelin-1, in order to proliferate
(BoÈhm et al, 1995), melanoma cell lines established from later stages
gradually and become increasingly independent of exogenous
mitogens (Halaban, 1996).
In parallel to gradual independence of exogenous mitogens,
melanoma cell lines derived from different stages progressively lose
their sensitivity towards certain growth-inhibitory cytokines. This
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phenomenon was coined ``multicytokine resistance'' (Kerbel,
1992) and has been substantiated for a number of cytokines,
including interleukin (IL) -1, IL-6, transforming growth factor-b,
and oncostatin M (Cornil et al, 1991; Lu et al, 1992, 1993; Lu and
Kerbel, 1993; Rodeck et al, 1994). The signi®cance of growth
inhibitors has also been demonstrated in vivo. For example, mouse
melanocytes transduced by dominantly acting oncogenes such as
E1A, neu, or ras, or those ectopically expressing cDNA for bFGF,
are inhibited in their growth by keratinocytes after cografting
(Dotto et al, 1989). Fibroblasts or conditioned medium obtained
from these cells contain a soluble factor capable of inhibiting the
growth of melanoma cells, which was later identi®ed as IL-6
(Cornil et al, 1991; Lu et al, 1992). IL-6 suppresses the growth of
melanoma cells derived from early stages by G1/G0 arrest, whereas
a large proportion of melanoma cell lines derived from advanced
stages are resistant (Lu et al, 1992). Subsequent studies have revealed
no differences in the expression of the IL-6Ra subunit (gp80) and
the signal converting molecule gp130 between IL-6 sensitive and
resistant cell lines (Lu and Kerbel, 1993). These ®ndings suggest
disturbances within the IL-6 signal transduction and/or cell cycle
machinery to be responsible for the stunted response of advanced
melanoma cell lines towards IL-6.
In order to elucidate the molecular base for the IL-6 resistance of
advanced stage-derived melanoma cells, we examined critical cell
cycle regulators implicated in G1 arrest and the signal transduction
of IL-6. We utilized two melanoma cell lines, WM35, derived
from a RGP early melanoma and arrested by IL-6, and WM9,
established from a late (metastatic) lesion and insensitive to IL-6 (Lu
et al, 1992). These cell lines have been previously shown not to
differ with respect to IL-6Ra and gp130 expression as well as their
IL-6 binding af®nity, thus representing a suitable model for our
studies. Treatment of WM35 melanoma cells with IL-6 leads to
inhibition of cyclin E-associated kinase activity and accumulation
of hypophosphorylated retinoblastoma protein (RB), whereas in
WM9 cells these parameters are only marginally affected.
Examination of the upstream signaling molecules of these IL-6-
mediated effects disclosed markedly reduced activation of signal
transducer and activator of transcription 3 (STAT3) in WM9
melanoma cells. Our ®ndings provide a link between the STAT3
signal transduction and the mechanism of G1 arrest mediated by IL-
6 and give insight into the alterations of these pathways in human
melanoma as a function of tumor progression.
MATERIALS AND METHODS
Cell culture The human melanoma cell lines WM35 and WM9 were
obtained from Dr. M. Herlyn (The Wistar Institute, Philadelphia, PA).
WM35 is derived from an early stage primary tumor (RGP), whereas
WM9 was established from a late (metastatic) stage lesion (Herlyn et al,
1989; Herlyn, 1990). Cells were maintained in RPMI 1640 medium
with all supplements as described previously (BoÈhm et al, 1994).
Fluorescence-activated cell sorter and DNA content analysis For
¯uorescence-activated cell sorter analysis, cells were harvested by gentle
scraping into phosphate-buffered saline with a rubber policeman,
centrifuged and resuspended in 100 ml of phosphate-buffered saline
containing 1% bovine serum albumin. After incubation with 1 mg per
100 ml anti-human IL-6R antibody (UBI, Lake Placid, NY) for 1 h at
4°C, unbound antibody was washed off and cells were incubated with a
¯uorescein isothiocyanate-conjugated anti-rabbit antibody for 30 min.
After washing and resuspension in phosphate-buffered saline, cells were
analyzed in the presence of propidium iodide in an EPICS VL ¯ow
cytometer (Coulter, Miami, FL). For DNA analysis, cells were seeded
into 100 mm dishes in regular culture medium and switched to RPMI
1640 containing 2% fetal bovine serum after adherence. Recombinant
human IL-6 (30 ng per ml) was added and cells were harvested by
trypsinization 36 h later. DNA content analysis was determined by ¯ow
cytometry as described previously (Herzinger et al, 1995).
Immunoprecipitation and immunoblot analysis Melanoma cells
seeded into 100 mm Petri dishes were kept in RPMI 1640 without fetal
bovine serum for at least 24 h prior to stimulation with recombinant
human IL-6 (30 ng per ml). Immunoprecipitation and immunoblot
procedures were the same as described before (BoÈhm et al, 1995; Funk
et al, 1997). For Western immunoblotting of total cell extracts, identical
amounts of lysate protein (usually 20 mg per lane) were separated by
sodium dodecyl sulfate±polyacrylamide gel electrophoresis (SDS±PAGE),
or alternatively by the NuPAGE system from Novex (Invitrogen,
Groningen, the Netherlands). For immunoprecipitation, identical amounts
of lysate proteins (500 mg) in lysis buffer were incubated with the
indicated antibodies overnight at 4°C followed by the addition of protein
A/G agarose. After 1 additional hour and extensive washing with lysis
buffer, immune complexes were eluted with 35 ml 2 3 SDS sample buffer
for 5 min at 95°C, followed by SDS±PAGE and western blotting. PVDF
membranes were probed with the respective antibodies and signals were
generated with the ECL detection system and horseradish peroxidase-
coupled secondary antibodies (Amersham, Piscataway, NJ). The antibodies
were: anti-phospho-Tyr705-STAT3 (New England Biolabs, Beverly,
MA); anti-phospho-Tyr1022/1023-Janus kinase (JAK) 1 (Biosource
International, Camarillo, CA); anti-cyclin E, anti-p27Kip1, anti-cdc25A
and anti-STAT3 (Santa Cruz Biotechnology, Santa Cruz, CA); anti-
p21Cip1/WAF1 and anti-a-tubulin (Calbiochem, San Diego, CA); anti-
phosphotyrosine, anti-cyclin-dependent kinase (cdk) 2, anti-JAK2, anti-RB,
anti-JAK1, and Tyk2 (PharMingen, San Diego, CA). In general,
immunoblots were repeated at least twice. In some experiments, the ®rst
immunoblot was stripped off as described previously (BoÈhm et al, 1995).
Immuno¯uorescence studies Melanoma cells seeded on to
polystyrene tissue chamber slides were kept in serum-free RPMI 1640
medium for 24 h before stimulation with IL-6. After ®xation with 4%
paraformaldehyde and aldehyde quenching with 50 mM NH4Cl, cells
were permeabilized with methanol for 10 min at ±20°C. Unspeci®c
binding was blocked with 5% goat/donkey serum and cells were
incubated for 2 h at room temperature with an anti-STAT3 polyclonal
antibody (1:100, Santa Cruz) and a mouse monoclonal antibody against
protein disul®de isomerase (1:100, Dako, Hamburg, Germany). After
extensive washing, bound antibodies were visualized by secondary
donkey anti-rabbit antibodies conjugated with Texas red (1:100,
Dianova, Hamburg, Germany) and goat anti-mouse antibodies coupled
to ¯uorescein isothiocyanate (1:100, Dako). Slides were mounted and
examined by confocal laser-scanning microscopy. Subcellular localization
of STAT3 was assessed by viewing three independent microscopic ®elds
with 100 cells per experiment. Experiments were performed in triplicate.
Statistical signi®cance between WM35 and WM9 cells was calculated by
the Student's t test.
Electrophoretic mobility shift assay After stimulation with IL-6,
cells were swollen in hypotonic buffer as described (Aragane et al, 1998).
After addition of Nonidet P-40, cell suspensions were minifuged and
pellets containing the nuclear proteins resuspended in hypertonic buffer
(hypotonic buffer supplemented with 0.4 M NaCl), incubated for
15 min on ice, and centrifuged. Protein concentrations were measured
by the Bio-Rad protein assay (Bio-Rad, MuÈnchen, Germany) and
electrophoretic mobility shift assay were performed as described
previously (Gerhartz et al, 1996). The g-32P-labeled mutated double-
stranded oligonucleotide corresponding to sis-induced element of the fos
promoter (m67: 5¢-GATCCGGGAGGGATTTACGGGGAAATGCTG-
3¢) was used as a probe (Wagner et al, 1990). DNA±protein complexes
were separated on a 4.5% polyacrylamide gel, ®xed, dried, and
autoradiographed. Signals were quanti®ed with a phosphorimager. For
supershift assays, nuclear extracts were preincubated with 2 ml of anti-
STAT3a anti-serum (kindly provided by Dr. Werner MuÈller-Esterl,
Frankfurt, Germany) for 15 min on ice.
Histone H1 (HH1) kinase assays Preparation of cell extracts was
identical to that described before (Herzinger et al, 1995). Identical
amounts of lysate proteins (100 mg per assay) were adjusted to a volume of
700 ml with lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM
ethylenediamine tetraacetic acid, 2.5 mM ethyleneglycol-bis-(b-amino-
ethylether)-N,N,N¢,N¢-tetraacetic acid, 0.1 mM Na3VO4, 1 M NaF,
10 mM glycerophosphate, 10% glycerol, 0.1% Tween, and freshly added
protease inhibitors) and anti-cdk2 or cyclin E antibody was added.
Mixtures were rotated overnight at 4°C and immune complexes collected
by binding to protein A agarose beads followed by three washes with lysis
buffer. The beads were washed in kinase buffer (20 mM MgCl2, 10 mM
ethyleneglycol-bis-(b-aminoethylether)-N,N,N¢,N¢-tetraacetic acid, 40 mM
HEPES, pH 7.0). Kinase reactions were performed in 20 ml kinase buffer
containing 0.5 ml of g-32P-adenosine triphosphate (300 Ci per mmol) and
1 mg of HH1 (Boehringer, Mannheim, Germany) at 30°C for 20 min and
stopped by addition of 20 ml of 2 3 SDS sample buffer. After SDS±
PAGE, signals were analyzed by autoradiography and quanti®ed with a
phosphorimager.
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MEK1 assay A commercially available immunoprecipitation kinase
assay (UBI) was used for determining MEK1 activity. The test is based
on MEK1-dependent activation of MAPK2/ERK2. In short, 100 ml of
protein A/G agarose slurry was preincubated with 10 ml of an anti-
MEK1 polyclonal antibody (UBI) overnight, washed in phosphate-
buffered saline and incubated with 1 mg of whole cell lysate (prepared as
described above and normalized for protein content), 1.0 U of
recombinant human active MEK1 (positive control) or, with cell lysate
without the MEK1 antibody (negative control). After
immunoprecipitation, 20 ml of assay dilution buffer, magnesium/
adenosine triphosphate cocktail containing g-32P-adenosine triphosphate
and 1.6 ml of inactive recombinant glutathione-S-transferase-MAPK2
were added and incubated with the protein A agarose immunocomplex
for 30 min at 30°C. Four microliters of the supernatant was incubated
with myelin basic protein, magnesium/adenosine triphosphate cocktail
for further 10 min. The reaction was stopped by transferring 25 ml of the
reaction mixture on to P81 phosphocellulose paper, followed by
thorough washing and liquid scintillation. Speci®c enzyme activity was
measured against recombinant MEK1 minus negative control and
statistical signi®cance was calculated by the Student's t test. To monitor
equal amounts of immunoprecipitated MEK1, supernatants were
carefully removed from the agarose beads. MEK1 was eluted by adding
25 ml 2 3 SDS sample buffer followed by western immunoblotting with
an anti-MEK1 monoclonal antibody (Transduction Laboratories,
Lexington, KY).
RESULTS
IL-6 affects cyclin E-associated kinase activity and
phosphorylation of RB in WM35 and WM9 cells
differently In order to study the comparative effect of IL-6 on
the activity of distinct cell cycle regulators implicated in G1 arrest,
we ®rst recon®rmed the differential growth-inhibitory effect of IL-
6 on WM35 and WM9 melanoma cells (Lu et al, 1992). IL-6
(30 ng per ml) increased in WM35 cells the percentage of cells in
G1 after 36 h, whereas no signi®cant changes were detected in
WM9 cells (data not shown). In addition, ¯uorescence-activated
cell sorter analysis using IL-6R antibodies showed an identical
mean ¯uorescence intensity for WM35 and WM9 cells suggesting
no differences in IL-6R expression (data not shown). This is in
accordance with previous ®ndings detecting no differences in IL-6
binding af®nity and expression of both the IL-6Ra subunit (gp80)
and the signal converting subunit gp130 (IL-6Ra) between IL-6
resistant and sensitive melanoma cell lines (Lu and Kerbel, 1993).
Passage through G1 into S phase is governed by a family of cdk
whose activity is regulated by binding to cyclins, phosphorylation/
dephosphorylation, and association with low-molecular weight cdk
inhibitors. Transition through the G1 phase is sequentially
governed by cdk4/6-cyclin D complexes and by cdk2±cyclin E
complexes. Cdk2/cyclin E activity peaks at the G1 to S transition
and constitutes one prerequisite signal for entry into S phase
(Morgan, 1995; Sherr and Roberts, 1995; Funk and Galloway,
1998). We therefore examined the effect of IL-6 in WM35 and
WM9 melanoma cells on the activity of cdk2/cyclin E.
Immunoprecipitation of cyclin E and in vitro kinase assays using
HH1 as a substrate revealed pronounced inhibition of cyclin-E-
associated kinase activity as early as 8 h after stimulation with IL-6
in WM35 cells (Fig 1A, B). After 36 h, cyclin E-associated kinase
activity was suppressed to less than 25% compared with cells not
treated with IL-6. In contrast, cyclin E-associated kinase activity
was only marginally affected by IL-6 in WM9 melanoma cells
(Fig 1A, B). Equivalent results were obtained when cdk2 was
immunoprecipitated and assayed for its kinase activity using HH1
(data not shown).
One substrate for G1 cyclin±cdk complexes, including cyclin E/
cdk2 is RB. RB becomes increasingly phosphorylated in late G1
(Weinberg, 1995; Bartek et al, 1996). Only the hypophosphory-
lated RB can bind to and thereby inactivate the transcription factor
Figure 1. IL-6 regulates cyclin E-associated kinase activity and
phosphorylation of RB in WM35 but not in WM9 melanoma
cells. Phosphorimage analysis of cyclin E-associated kinase activity in
both cell lines after treatment with IL-6 for various time periods as
indicated (A). After treatment with IL-6, cells were lyzed and subjected
to immunoprecipitation with antibodies against cyclin E. Puri®ed
immune complexes were subsequently incubated for 20 min in kinase
buffer containing g-32P-adenosine triphosphate and HH1 as a substrate.
Phosphorylated HH1 was separated by 12% SDS±PAGE followed by
autoradiography (B). Total cellular extracts (20 mg protein per lane) were
separated by 6% SDS±PAGE followed by western immunoblotting with
an antibody that recognizes both the hyperphosphorylated (upper
migrating) and hypophosphorylated (lower migrating) form of RB (C).
Figure 2. IL-6 does not affect expression of cdk2, cyclin E,
p21Cip1/WAF1, p27Kip1 and cdc25A. After stimulation with IL-6 (30 ng
per ml), 20 mg protein derived from whole cell extracts were separated
by 4±12% gradient gels using the NuPAGE system followed by western
blotting and sequential probing with the indicated antibodies (A).
Amounts of p21Cip1/WAF1 and p27Kip1 bound to cdk2 after IL-6
treatment as assessed by coimmunoprecipitation (IP). Cell lysates (300 mg
protein) were incubated with an anti-cdk2 antibody and immunoblotted
(IB) with antip21Cip1/WAF1 and antip27Kip1 antibodies (B).
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E2F whose activity is required for the S phase. Treatment of
WM35 melanoma cells with IL-6 resulted in the accumulation of
hypophosphorylated RB as demonstrated by its faster migration in
low percentage SDS±PAGE and western immunoblotting
(Fig 1C). The shift from the phosphorylated to the nonpho-
sphorylated form was observed in WM35 cells 16 h after IL-6
treatment. At 24 and 36 h only dephosphorylated RB was
detectable in WM35 cells. In contrast, in WM9 cells levels of
phosphorylated RB remained constant after IL-6 treatment at all
time points. Thus, the RB changes in the phosphorylation status
parallel the regulation of cdk2±cyclin E activity.
IL-6 does not affect expression of cdk2, cyclin E, cdc25A,
p21Cip1/WAF1 and p27Kip1 To elucidate further the mechanism
of IL-6-mediated inhibition of cyclin E-associated kinase activity
and to check if IL-6 unresponsive WM9 cells display differences in
cdk2 regulation, we ®rst examined the expression of cyclin E and
cdk2 in whole cell extracts. Western blot analysis revealed that the
protein levels of cyclin E and cdk2 in both cell lines did not change
upon treatment with IL-6 (Fig 2A). Protein levels of cdk2,
however, were consistently lower in WM9 cells compared with
WM35 cells. In addition, the protein levels of cdc25A, a dual-
speci®c phosphatase activating cdk2 by dephosphorylating cdk2
at Thr14 and Tyr15 (Hoffmann et al, 1994), remained constant
in total cell extracts of WM35 and WM9 cells, respectively
(Fig 2A).
Next, we analyzed expression and binding of the KIP family
members p21Cip1/WAF1 and p27Kip1. It is known that a number of
growth arrest signals such as DNA damaging agents or transforming
growth factor-b lead to transcriptional activation and increased
protein expression of these low-molecular weight cdk2 inhibitors
(Massague and Polyak, 1995; Sherr and Roberts, 1995). Whereas
the KIP family members inhibit a wide range of cdk, members of
the INK family preferentially inhibit cyclin D-associated kinases,
i.e., cdk4 and cdk6. As WM35 melanoma cells, however, lack
expression of p16INK4A and p15INK4B (Bani et al, 1996; Florenes et
al, 1996; our own unpublished ®ndings), we examined the
expression of p21Cip1/WAF1 and p27Kip1. Expression of these cdk
inhibitors was low on the protein level in both cell lines albeit
p21Cip1/WAF1 was expressed at higher levels in WM9 cells as
compared with WM35 cells (Fig 2A). Treatment of WM35 and
WM9 cells with IL-6, however, did not result in any signi®cant
changes in the protein levels of p21Cip1/WAF1 and p27Kip1. To
ascertain that identical amounts of lysate proteins were analyzed in
all of these experiments, the membranes were ®nally re-probed
with an antibody against a-tubulin (Fig 2A).
As the total amount of p21Cip1/WAF1 and p27Kip1 found in whole
cellular extracts does not necessarily correlate with the fraction
bound to cdk2, co-immunoprecipitation experiments were per-
formed. Immunoprecipitation of cdk2 in both cell lines and
immunoblotting with antibodies against p21Cip1/WAF1 and p27Kip1,
however, did not reveal any differences in the amount of these cdk
inhibitors bound to cdk2 (Fig 2B).
DNA binding of STAT3 is signi®cantly impaired in WM9
melanoma cells As no differential regulation of cdk2 by CKI in
WM35 and WM9 cells after IL-6 treatment could be detected, we
wondered if changes upstream of the cell cycle machinery, namely
within the signal transduction of IL-6 are responsible for the IL-6
resistance of WM9 cells. Elicitation of the diversity of biologic
effects by IL-6 on target cells is stringently dependent on activation
of STAT3, a latent transcription factor that becomes activated by
tyrosine phosphorylation after the binding of IL-6 to its receptor
(Darnell, 1997; Heinrich et al, 1998). STAT3 subsequently
dimerizes, translocates to the nucleus where it binds to response
elements consisting of the palindromic consensus oligonucleotide
sequence TTCC(C/G)GGGAA.
Thus, we prepared nuclear extracts of WM35 and WM9
melanoma cells after stimulation with IL-6 and analyzed DNA
binding of STAT3 using a high-af®nity sis-inducible element of the
c-fos promoter as a probe in the electrophoretic mobility shift assay
(Wagner et al, 1990). A weak constitutive DNA±protein complex
formation was detectable in both cell lines (Fig 3, left). This basal
DNA±protein complex formation was not due to suboptimal fetal
bovine serum deprivation as both cell lines had been kept in serum-
free medium for at least 24 h. Stimulation with IL-6 (30 ng per ml)
resulted in a rapid increase in DNA±protein complex formation.
Densitometric analysis revealed that this DNA±protein complex
formation peaked between 30 and 60 min after stimulation with
IL-6 in both cell lines (Fig 3, left). DNA±protein complex
formation in WM35 cells, however, was markedly enhanced and
prolonged compared with WM9 cells. Whereas the DNA±protein
complex formation in WM35 melanoma cells remained elevated as
long as 240 min after IL-6 treatment, it returned in WM9 cells
almost to the basal level at this time point (Fig 3, left).
In order to con®rm the speci®city of the detected DNA±protein
complexes, ``supershift'' experiments with a STAT3a-speci®c
antibody were performed (Fig 3, right). Addition of the antibody
to nuclear extracts of IL-6-stimulated cells resulted in a speci®c
shift. In unstimulated cells, no supershift was observed (Fig 3,
right), although constitutive DNA±protein complex formation was
present (Fig 3, left). This is explained by the nature of the antibody
that does not only bind to the STAT3 protein but also interferes
with the transcription factor-STAT3 oligonucleotide probe inter-
action, as observed previously (Haan et al, 2000). In accordance
with this ®nding, the ``supershift'' band for the untreated cells is
virtually invisible as would be expected from the much lower level
of DNA binding of STAT3 in nuclear extracts of these cells.
Differential subcellular localization of STAT3 in WM35 and
WM9 melanoma cells One possible explanation for impaired
nuclear binding of STAT3 in WM9 melanoma cells could be
reduced nuclear translocation upon stimulation with IL-6. Thus,
we examined the subcellular distribution, nuclear translocation, and
redistribution of STAT3 following stimulation with IL-6 by double
immuno¯uorescence using a monoclonal antibody against protein
disul®de isomerase, which served as a cytoplasmic marker (Munro
and Pelham, 1986; Vaux et al, 1990). STAT3 was detected by a
polyclonal antibody. The percentage of cells displaying a diffuse,
Figure 3. STAT3-DNA complex formation in WM35 and WM9
cells upon IL-6 treatment. Cells were kept in serum-free medium for
24 h and were then treated with IL-6 (30 ng per ml). Nuclear extracts
were prepared at the indicated time points and were incubated with the
g-32P-labeled double-stranded oligonucleotide m67 corresponding to the
sis-induced element of the fos promoter. DNA±protein complexes were
separated on a 4.5% polyacrylamide gel and autoradiographed. Intensity
of the bands was also quanti®ed by densitometric analysis. Speci®city of
the DNA±protein complexes was con®rmed by supershift assays in
which nuclear extracts were incubated with 1 ml of anti-STAT3a
antiserum. Data represent one set of two independent experiments with
similar results.
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perinuclear, or nuclear staining was evaluated at different time
points after IL-6 treatment (Table I).
Both cell lines exhibited diffuse immunostaining in which
STAT3 was localized in the cytoplasm and to a lesser degree in the
nucleus prior to stimulation with IL-6 (Figs 4 and 5, for
representative ®elds). Within 30 min after IL-6 treatment, STAT3
was found mainly in the nuclei of WM35 cells, whereas in WM9
cells most of the STAT3 was still distributed diffusely or con®ned
to the perinuclear region (Figs 4 and 5). Sixty minutes after IL-6
exposure, most of the STAT3 was translocated to the nucleus in
both cell lines, although WM35 still contained statistically more
STAT3 in the nuclei. This difference was again further pronounced
240 min after IL-6 exposure, at which most of the STAT3 was
already relocalized to the cytoplasm in WM9 cells, whereas more
than 50% of the nuclei of WM35 melanoma cells still contained
STAT3 and presented a mixed cytoplasmic/nuclear staining almost
indistinguishable from the staining pattern obtained 30 min after
stimulation (Figs 4 and 5). Protein disul®de isomerase as the
cytoplasmic marker was always con®ned to the rough endoplasmic
reticulum (Munro and Pelham, 1986; Vaux et al, 1990) (Figs 4
and 5). These observations show that STAT3 indeed is translocated
to the nucleus in WM9 melanoma cells after stimulation with IL-6.
In comparison with WM35 cells, however, quantitative differences
exist with respect to the proportion of STAT3 being transferred to
the nucleus at a given time period after IL-6 treatment and the
speed of cytoplasmic relocation.
Reduced tyrosine phosphorylation of STAT3 in WM9
melanoma cells Regular function and transcriptional activity
of STAT3 has been linked to two critical phosphorylation sites
located at the carboxy-terminal end of the molecule. Whereas
phosphorylation at Tyr705 has been clearly shown to correlate
positively with DNA binding, dimerization, and nuclear
translocation of STAT3 (Darnell, 1997; Heinrich et al, 1998), the
role of Ser727 phosphorylation remains controversial (Zhang et al,
1995; Wen and Darnell, 1997; Wen et al, 1995). Immuno-
precipitation of STAT3 from WM35 and WM9 melanoma cell
extracts and immunoprobing with anti-STAT3 antibodies showed
identical levels of STAT3 protein in unstimulated and IL-6-treated
cell lines (Fig 6A, C). Thus, impaired DNA binding of STAT3 in
WM9 cells is not due to reduced protein expression. When STAT3
was immunoprecipitated and the membrane probed with a site-
speci®c anti-phospho-Tyr705-STAT3 antibody (or, an anti-
phosphotyrosine antibody), both cell lines showed weak basal
phosphorylation of STAT3 without IL-6 treatment (Fig 6B, C).
The constitutive tyrosine phosphorylation of STAT3 was in
accordance with the observed constitutive DNA binding as
shown above and was not due to suboptimal deprivation as both
cell lines had been deprived under serum-free conditions for at least
24 h. Upon IL-6 treatment, WM9 cells displayed markedly
reduced phosphorylation compared with WM35 cells (Fig 6B,
C), suggesting that the IL-6 resistance of advanced melanoma cell
lines is due to a defect in STAT3 tyrosine phosphorylation.
Loss of IL-6-induced activation of JAK1 in WM9 melanoma
cells IL-6 leads to the activation of a number of nonreceptor
tyrosine kinases known as the Janus kinases (JAK1, JAK2, and
Tyk2). Extent and pattern of activation of these kinases following
IL-6 treatment appears to be cell-type speci®c (LuÈtticken et al,
1994; Stahl et al, 1994). As the stunted response of WM9 cells to
IL-6 could be due to the downregulation of JAK, we ®rst examined
the expression of JAK in WM35 and WM9 cells. Western blot
analysis of total cell lysates with speci®c antibodies against JAK1,
JAK2, and Tyk2 revealed similar amounts of protein in both cell
lines (Fig 7A).
Table I. Differential subcellular localization of STAT3 in
WM35 and WM9 cells after IL-6 treatment
IL-6a
(min)
Localization in percentageb
Diffuse Perinuclear Nuclear
WM35
± 91.6 6 3.1* 2.3 6 1.5** 6.0 6 1.7**
30 15.0 6 4.4** 17.7 6 2.5** 67.0 6 6.8*
60 11.0 6 3.6** 11.7 6 2.5** 77.3 6 1.2*
240 25.0 6 4.5* 18.6 6 1.5** 56.0 6 4.4*
WM9
± 77.3 6 3.5* 12.0 6 2.0** 10.6 6 2.9**
30 34.3 6 6.7** 51.3 6 5.0** 14.3 6 2.5*
60 7.7 6 4.0** 24.7 6 4.5** 67.7 6 2.5*
240 53.0 + 5.3* 29.0 6 4.0** 18.0 6 2.0*
aCells were stimulated with IL-6 (30 ng per ml) and localization of STAT3 was
determined by double immuno¯uorescence with a monoclonal anti-STAT3 anti-
body and a polyclonal antibody against protein disul®de isomerase, a cytoplasmic
marker. Bound antibodies were visualized by secondary antibodies conjugated to
Texas red and ¯uorescein isothiocyanate, respectively.
bData represent the mean 6 SD from viewing three independent microscopic
areas, each with 100 cells per experiment. Experiments were performed in tripli-
cate. Signi®cance of STAT3 localization per time point between WM35 and
WM9,
*p < 0.01;
**p < 0.05.
Figure 4. Subcellular distribution of STAT3 in WM35 cells after
treatment with IL-6 (30 ng per ml). Cells were ®xed with methanol
and double stained for STAT3 (red ¯uorescence) and a marker for the
endoplasmic reticulum (green ¯uorescence). Cells were left untreated (A,
D) or were stimulated with IL-6 for 30 min (B, E) and 240 min (C, F).
Note nuclear staining of STAT3 after IL-6 treatment for 30 min.
Pictures are representative ®elds of three independent experiments. Scale
bar: 20 mm.
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We next addressed the question whether differences in the
extent of tyrosine phosphorylation of JAK may account for the
impaired activation of STAT3 in WM9 cells. As it was demon-
strated that STAT3 activation crucially depends on the presence
and proper activation of JAK1 only (Guschin et al, 1995), we
checked the tyrosine phosphorylation of JAK1 in WM35 and
WM9 cells lines upon stimulation with IL-6 (30 ng per ml).
Immunoblot analysis of crude cell extracts with an antibody that
speci®cally recognizes JAK1 phosphorylated on Tyr1022 and
Tyr1023 con®rmed phosphorylation within 5 min (Fig 7B, left)
in WM35 cells. WM9 cells, in contrast, displayed prominent
constitutive tyrosine phosphorylation of JAK1 with no increment
upon IL-6 treatment (Fig 7B, right). Prolonged treatment of WM9
cells with IL-6 for up to 30 min did not result in any increment in
tyrosine phosphorylation of JAK1 (data not shown). These ®ndings
suggest that the defect in STAT3 activation in WM9 cells is linked
to the defective activation of JAK1.
Differential activity of MEK1 in WM35 and WM9 melanoma
cells The Ras-Raf-MAPKK-MAPK (mitogen-activated protein
kinase) pathway has been shown to become synergistically activated
in response to distinct melanocyte peptide growth factors (BoÈhm et
al, 1995) among which bFGF was identi®ed as an autocrine growth
factor for melanoma. As the MAPK signaling cascade was shown to
suppress STAT3 and JAK1 tyrosine phosphorylation (Ceresa et al,
1997; Jain et al, 1998; Sengupta et al, 1998) we thus examined the
expression and activity of MAPK kinase 1 (MAPKK1 or MEK1) in
WM35 and WM9 cells.
Unexpectedly, MEK1 kinase activity in nonstimulated WM9
cells was signi®cantly lower than in WM35 cells (Fig 8A). Upon
stimulation with IL-6 (30 ng per ml) for 30 min MEK1 activity in
WM35 cells declined but rose to the level of unstimulated cells
within 36 h. In contrast, no changes in MEK1 activity could be
detected after IL-6 treatment in WM9 cells. The differential MEK1
activity between WM35 and WM9 cells was not due to the
reduced expression of MEK1 protein as the amount of MEK1
eluted from the immune complexes was similar (Fig 8B). These
data demonstrate that MEK1 activity in WM9 cells is not increased
and do not support the concept that the reduction of IL-6-induced
STAT3 activation in WM9 cells is related to increased MEK1
activity.
Figure 5. Subcellular distribution of STAT3 in WM9 cells after
treatment with IL-6 (30 ng per ml). Cells were ®xed with methanol
and double stained for STAT3 (red ¯uorescence) and a marker for the
endoplasmic reticulum (green ¯uorescence). Cells were left untreated (A,
D) or were stimulated with IL-6 for 30 min (B, E) and 240 min (C, F).
Note prominent diffuse staining of STAT3 in cells stimulated with IL-6
for 30 min as well as accelerated cytoplasmic relocation of STAT3 after
stimulation with IL-6 for 240 min. Pictures are representative ®elds of
three independent experiments. Scale bar: 20 mm.
Figure 6. Reduced tyrosine phosphorylation of STAT3 in WM9
cells after IL-6 treatment. Cells were kept in serum-free medium for
24 h followed by stimulation with IL-6 (30 ng per ml) for 30 min. Cells
lysates were subjected to immunoprecipitation (IP) with an anti-STAT3
antibody and 8% SDS±PAGE. Membranes were immunoblotted (IB)
with a phospho-speci®c antibody that speci®cally recognizes STAT3 at
Tyr705. Membranes were subsequently stripped and reprobed with an
anti-STAT3 antibody. Tyrosine phosphorylation of STAT3 is shown in
(A), STAT3 protein expression in (B). Bands were evaluated
densitometrically (C). *Antibody band derived from cross-reaction of the
secondary antibody with the antibody used for the IP.
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DISCUSSION
We have examined comparatively the effect of IL-6 on the signal
transduction and regulation of distinct cell cycle players in the
human melanoma cell lines WM35 and WM9 in order to decipher
the molecular mechanism by which melanoma cells derived from
advanced stages become resistant to IL-6. With regard to the cell
cycle, our ®ndings show that the cyclin E/cdk2 complex as well as
RB are both target molecules for the growth-inhibitory action of
IL-6. The observed inhibition of cdk2 and the accumulation of the
hypophosphorylated (active) form of RB in WM35 cells upon IL-6
treatment are in accordance with recent ®ndings from others
(Florenes et al, 1999). In contrast to the latter investigators we did
not detect an inductive effect on the p21Cip1/WAF1 protein
expression that could account for the rapid inhibition of cdk2/
cyclin E activity in WM35 cells upon IL-6 treatment. This ®nding
was con®rmed by repetitive immunoblot analysis of whole cell
extracts as well as by co-immunoprecipitation experiments in
which the actual amount of p21Cip1/WAF1 bound to cdk2 was
evaluated at various time points after IL-6 treatment. The
discrepancies between our data and the ®ndings from Florenes et
al (1999) with regard to p21Cip1/WAF1 may be related to differences
in culture conditions. In our study cells were treated with higher
IL-6 doses (30 ng per ml) and in the presence of higher amounts of
fetal bovine serum (2%) as compared with Florenes et al (1999)
(10 ng per ml IL-6, 1% fetal bovine serum). The WM35 melanoma
cell line was originally established by Herlyn et al (1989) more than
10 y ago. Thus, it is also possible that different clones of WM35
cells with a differential response to IL-6-induced p21Cip1/WAF1
expression have originated under long-term culture in the various
laboratories using this cell line.
Interestingly, the amounts of cdk2 and p27Kip1 at the protein
level, especially those of cdk2, were higher in WM35 than in WM9
cells. The stronger expression of p21Cip1/WAF1 in WM9 cells is in
accordance with ®ndings from others, who demonstrated that
invasive primary melanomas and metastatic melanomas in situ
express high levels of this low-molecular cdk inhibitor (Bales et al,
1999). The observed cell line-speci®c differences in p27Kip1 and
cdk2 expression, however, do not explain the effect of IL-6 on
cdk2 activity in WM35 cells. Recently, inhibition of cdk2 activity
in the absence of altered levels of p21Cip1/WAF1, p27Kip1 p57Kip2,
p15INK4b, and cdc25A has been reported in HepG2 cells treated
with transforming growth factor-b. The inactivation of cyclin E/
cdk2 complexes were caused by the absence of the Thr160
phosphorylation on cdk2 and associated with the inhibition of
Thr160 cdk activating kinase activity (Nagahara et al, 1999). It will
be interesting to check if an analogous mechanism of cdk2
inhibition also occurs in our WM35 cells. As IL-6-induced growth
arrest of another human melanoma cell line, A375, is associated
with the induction of p27Kip1 (Kortylewski et al, 1999), different
cell cycle players appear to be targeted by IL-6 depending on the
examined cell type and the experimental conditions.
Our comparative studies on the IL-6 signaling pathway, on the
other hand, disclosed a complex alteration in WM9 cells as
compared with WM35 cells. First, the functional state of STAT3
(as determined by DNA binding, tyrosine phosphorylation, and the
rate of nuclear translocation and cytoplasmic relocation) was altered
in WM9 cells. Second, JAK1, the upstream kinase of STAT3, did
not respond to IL-6 treatment in WM9 cells with the phosphoryla-
tion at Tyr1022/1023 but displayed constitutive phosphorylation.
Third, differences were found in both cell lines with respect to basal
and IL-6-regulated MEK1 activity. These ®ndings suggest that the
loss of IL-6 response and the subsequent abnormalities in cell cycle
Figure 7. WM9 cells display constitutive JAK1 tyrosine
phosphorylation and do not respond to IL-6 treatment with JAK1
activation. Identical amounts of protein in total cell lysates (30 mg per
lane) were separated by 4±12% NuPAGE gradient gels followed by
immunoblotting with the indicated antibodies (A). For phosphorylation
experiments, cells were stimulated with IL-6 (30 ng per ml) for 5 min
and were harvested directly in boiling sample buffer, followed by 8%
SDS±PAGE (100 mg protein per lane) and immunoblotting with an
antibody that speci®cally recognizes phosphorylated JAK1 on Tyr1022/
1023. The membrane was subsequently stripped and reprobed with an
anti-JAK1 antibody to assure identical amounts of protein (B).
Figure 8. Differential activity of MEK1 in WM35 and WM9. Cells
were stimulated with IL-6 (30 ng per ml) and MEK1 was
immunoprecipitated from 1 mg of cell lysate. Immunoprecipitates were
incubated with recombinant MAPK as a substrate and MAPK activity
was assessed by in vitro phosphorylation of myelin basic protein. Enzyme
activity of MEK1 in cell lysates was compared with 1.0 U of
recombinant active human MEK1 in three independent experiments;
data represent mean 6 SD, p < 0.001 (A). MEK1 protein expression was
monitored by eluting the immune complexes with SDS buffer,
separation on 4±12% gradient gels and immunoblotting with an anti-
MEK1 antibody (B).
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regulation at least in WM9 cells are a direct consequence of a
profound disturbance in the IL-6 signal transduction pathway. The
critical role of STAT3 as a key IL-6 signal intermediate has been
con®rmed by various studies, e.g., in myeloid leukemia M1
leukemia cells that respond to IL-6 with terminal differentiation
and growth arrest. Cell lines constitutively expressing dominant
negative forms of STAT3 do not respond any longer to IL-6
(Minami et al, 1996). As WM9 cells are known to secrete bioactive
IL-6 (Lu and Kerbel, 1993; Silvani et al, 1995) it has been suggested
that constitutive secretion may desensitize melanoma cells to IL-6;
however, although autonomous IL-6 secretion by WM9 cells may
lead to constitutive JAK1 tyrosine phosphorylation, the concomi-
tant reduction in STAT3 activation is not conceivable with a
simple feed-forward model. One explanation for these puzzling
®ndings is that several components of the IL-6 signal transduction
pathway (as well as components of ``cross-talking'' signaling
pathways) may be altered simultaneously. Candidates that mediate
downregulation of the IL-6-induced activation of STAT3 are the
suppressors of cytokine signaling (Endo et al, 1997; Naka et al,
1997; Starr et al, 1997; Nicholson and Hilton, 1998) and PIAS3
(Chung et al, 1997). Accordingly, abnormal expression of one of
these molecules in WM9 cells may lead to reduced activation of
STAT3 by IL-6, whereas JAK1 phosphorylation is maintained by
autonomous IL-6 production. Whether suppressors of cytokine
signaling or PIAS3 are actually involved in the abnormal response
of WM9 cells towards IL-6 is currently under investigation in our
laboratory (BoÈhm et al, unpublished ®ndings).
Our studies on MEK1 as a potential downregulator of STAT3
activation did not reveal an enhanced enzyme activity in WM9
cells as compared with WM35 cells. In fact, MEK1 activity in
WM9 cells was even lower than in WM35 cells, which is in
accordance with preliminary data from us showing a reduced
tyrosine phosphorylation and activity of MAPK1/2 in WM9 cells.
On the other hand, the MEK1 activity was signi®cantly inhibited
by IL-6 in WM35 cells in a transient fashion. This ®nding raises the
question as to whether the downregulation of MEK1 is required for
growth inhibition by IL-6. It is known that the melanocyte peptide
growth factors bFGF, hepatocyte growth factor, endothelin-1, and
mast cell growth factor activate the MAPK cascade in normal
human melanocytes (BoÈhm et al, 1995). The synergistic action of
these growth factors on proliferation was paralleled by an enhanced
and prolonged in vivo phosphorylation of MAPK2 and Raf. In
addition, the in vitro kinase activity of Raf using a glutathione-S-
transferase-MEK fusion protein as a substrate was synergistically
enhanced and sustained by the above mitogens. Preliminary data
from us have further shown (BoÈhm et al, unpublished ®ndings) that
proliferation of WM35 and WM9 cells is strongly inhibited by PD
098059, a speci®c MEK inhibitor (Alessi et al, 1995). Thus,
resistance of WM9 cells to IL-6 may possibly be linked to a
deregulated function of MEK1. To con®rm the potential role of
MEK1 in IL-6-mediated growth inhibition and in IL-6 resistance
of advanced melanoma cells, further studies are needed. In
accordance with an important role of the MAPK cascade in the
development of cytokine resistance of melanoma are the recent
®ndings by Shellman et al (2000). These authors demonstrated that
ectopic expression of activated N-ras in WM35 cells abrogates
growth inhibition by transforming growth factor-b and inhibits the
accumulation of hypophosphorylated RB.
In summary, we have shown here that IL-6 resistant WM9
melanoma cells exhibit a complex alteration in the IL-6 signal
transduction pathway that is associated with an altered response to
MEK1. Our ®ndings point to a signi®cance part for STAT3 as a
molecular correlate of melanoma progression whose targeting may
also offer potential therapeutic strategies for melanoma (Niu et al,
1999).
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